These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 30370041)

  • 41. Overview and comparison of the clinical scores in hidradenitis suppurativa: A real-life clinical data.
    Daoud M; Suppa M; Benhadou F; Daxhelet M; Njimi H; White J; Jemec G; Del Marmol V
    Front Med (Lausanne); 2023; 10():1145152. PubMed ID: 37138732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa.
    Gulliver WP; Jemec GB; Baker KA
    J Eur Acad Dermatol Venereol; 2012 Jul; 26(7):911-4. PubMed ID: 21605174
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials.
    van der Zee HH; Longcore M; Geng Z; Garg A
    J Eur Acad Dermatol Venereol; 2020 May; 34(5):1050-1056. PubMed ID: 31630445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data.
    Caposiena Caro RD; Chiricozzi A; Sechi A; Molinelli E; Venturini M; Candi E; Malvaso D; Peris K; Patrizi A; Offidani A; Calzavara-Pinton P; Bianchi L
    Ital J Dermatol Venerol; 2022 Jun; 157(3):240-246. PubMed ID: 34159775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES; Garnock-Jones KP; Keam SJ
    Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa.
    Fania L; Giovanardi G; Samela T; Caposiena D; Chiricozzi A; Antonelli F; Saraceni P; Elia F; Garcovich S; Ciccone D; Cannizzaro MV; Miraglia E; Iacovino C; Giustini S; Skroza N; Mambrin A; Potenza C; Bianchi L; Peris K; Abeni D
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887799
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New perspectives on the treatment of hidradenitis suppurativa.
    Amat-Samaranch V; Agut-Busquet E; Vilarrasa E; Puig L
    Ther Adv Chronic Dis; 2021; 12():20406223211055920. PubMed ID: 34840709
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
    Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Successful Treatment of Coexistent Acne Fulminans and Severe Hidradenitis Suppurativa with Adalimumab.
    Kontochristopoulos G; Agiasofitou E; Platsidaki E; Kapsiocha A; Gregoriou S; Rigopoulos D
    Skin Appendage Disord; 2021 Jun; 7(4):329-332. PubMed ID: 34307485
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab.
    Caposiena Caro RD; Chiricozzi A; Sechi A; Molinelli E; Venturini M; Candi E; DE Simone C; Peris K; Patrizi A; Offidani A; Calzavara-Pinton P; Bianchi L
    Ital J Dermatol Venerol; 2022 Apr; 157(2):137-141. PubMed ID: 33982548
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group.
    Zouboulis CC; Bechara FG; Dickinson-Blok JL; Gulliver W; Horváth B; Hughes R; Kimball AB; Kirby B; Martorell A; Podda M; Prens EP; Ring HC; Tzellos T; van der Zee HH; van Straalen KR; Vossen ARJV; Jemec GBE
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):19-31. PubMed ID: 30176066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunomodulatory drugs alone and adjuvant to surgery for hidradenitis suppurativa/acne inversa-A narrative review.
    Wollina U; Brzezinski P; Koch A; Philipp-Dormston WG
    Dermatol Ther; 2020 Nov; 33(6):e13877. PubMed ID: 32558202
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa.
    Leslie KS; Tripathi SV; Nguyen TV; Pauli M; Rosenblum MD
    J Am Acad Dermatol; 2014 Feb; 70(2):243-51. PubMed ID: 24314876
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems.
    Włodarek K; Stefaniak A; Matusiak Ł; Szepietowski JC
    Dermatology; 2020; 236(1):8-14. PubMed ID: 31487719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Burden of Hidradenitis Suppurativa: A Systematic Literature Review of Patient Reported Outcomes.
    Kimball AB; Kirby J; Ingram JR; Tran T; Pansar I; Ciaravino V; Willems D; Lewis-Mikhael AM; Tongbram V; Garg A
    Dermatol Ther (Heidelb); 2024 Jan; 14(1):83-98. PubMed ID: 38183616
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current Medical and Surgical Treatment of Hidradenitis Suppurativa-A Comprehensive Review.
    Ocker L; Abu Rached N; Seifert C; Scheel C; Bechara FG
    J Clin Med; 2022 Dec; 11(23):. PubMed ID: 36498816
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.
    Chernyshov PV; Zouboulis CC; Tomas-Aragones L; Jemec GB; Svensson A; Manolache L; Tzellos T; Sampogna F; Pustisek N; van der Zee HH; Marron SE; Spillekom-van Koulil S; Bewley A; Linder D; Abeni D; Szepietowski JC; Augustin M; Finlay AY
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1633-1643. PubMed ID: 31037773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital.
    Tsentemeidou A; Sotiriou E; Vakirlis E; Sideris N; Lallas A; Ioannides D
    Arch Dermatol Res; 2022 Apr; 314(3):301-305. PubMed ID: 33094412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series.
    Esme P; Botsali A; Akoglu G; Caliskan E
    Skin Appendage Disord; 2022 Jul; 8(4):342-345. PubMed ID: 35983467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.